TEAD Inhibitors Sensitize KRAS ^G12C Inhibitors via Dual Cell Cycle Arrest in KRAS ^G12C -Mutant NSCLC.

Autor: Tammaccaro SL; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Prigent P; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Le Bail JC; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Dos-Santos O; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Dassencourt L; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Eskandar M; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Buzy A; Bio Structure and Biophysics, Sanofi R&D, 94400 Vitry-sur-Seine, France., Venier O; Small Molecules Medicinal Chemistry, Sanofi R&D, 91380 Chilly-Mazarin, France., Guillemot JC; Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France., Veeranagouda Y; Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France., Didier M; Genomics and Proteomics, Translational Sciences, Sanofi R&D, 91380 Chilly-Mazarin, France., Spanakis E; Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Kanno T; Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Cesaroni M; Precision Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Mathieu S; Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Canard L; Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Casse A; Molecular & Digital Histopathology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Windenberger F; Non-Clinical Efficacy and Safety, Sanofi R&D, 94400 Vitry-sur-Seine, France., Calvet L; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Noblet L; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Sidhu S; Pharmacology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Debussche L; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Moll J; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France., Valtingojer I; Oncology, Sanofi R&D, 94400 Vitry-sur-Seine, France.

Publikováno v: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2023 Apr 06; Vol. 16 (4). Date of Electronic Publication: 2023 Apr 06.

Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes

Autor: Frédéric DE CEUNINCK, Caliez, A., Dassencourt, L., Anract, P., Renard, P.

Publikováno v: Arthritis Research & Therapy
Scopus-Elsevier

Insulin-like growth factor 1 (IGF-1) has poor anabolic efficacy in cartilage in osteoarthritis (OA), partly because of its sequestration by abnormally high levels of extracellular IGF-binding proteins (IGFBPs). We studied the effect of NBI-31772, a s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6776e4f46940b2e73cd8a1db57c4ed55
http://europepmc.org/articles/PMC546277

Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells.

Autor: Oliveira, Susana Mendonça^1,2,3,4 (AUTHOR) smendonca@ipatimup.pt, Carvalho, Patrícia Dias^1,2,5 (AUTHOR) poliveira@ipatimup.pt, Serra-Roma, André^1,2 (AUTHOR) jcarvalho@ipatimup.pt, Oliveira, Patrícia^1,2 (AUTHOR) flaviam@ipatimup.pt, Ribeiro, Andreia^1,2 (AUTHOR) almachado@i3s.up.pt, Carvalho, Joana^1,2 (AUTHOR) mariajo@i3s.up.pt, Martins, Flávia^1,2,3 (AUTHOR), Machado, Ana Luísa^1,3,4 (AUTHOR), Oliveira, Maria José^1,3,5,6 (AUTHOR), Velho, Sérgia^1,2 (AUTHOR) svelho@i3s.up.pt

Publikováno v: Cancers. Jul2024, Vol. 16 Issue 14, p2595. 19p.

KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.

Autor: Ash, Leonard J.^1,2 (AUTHOR), Busia-Bourdain, Ottavia¹ (AUTHOR), Okpattah, Daniel³ (AUTHOR), Kamel, Avrosina^1,4 (AUTHOR), Liberchuk, Ariel^1,4 (AUTHOR), Wolfe, Andrew L.^1,2,3,5 (AUTHOR) awolfe@genectr.hunter.cuny.edu

Publikováno v: Current Oncology. Apr2024, Vol. 31 Issue 4, p2024-2046. 23p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.